Clouds Darken Over Gilead's Zydelig In Europe Amid EMA Review
This article was originally published in Scrip
Executive Summary
A fresh obstacle to Gilead Sciences Inc.'s blood cancer therapy Zydelig (idelalisib) is looming amid news the European Medicines Agency is reviewing the PI3K inhibitor's safety profile after a jump in serious adverse events, including deaths, mostly due to infections, observed in three clinical studies.